# Neoadjuvant Darovasertib in Primary Uveal Melanoma

Source: https://onco.cc/trials/nct07015190/  
OnCo record `nct07015190` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Darovasertib in uveal melanoma, now recruiting.

## Summary

Neoadjuvant Darovasertib in Primary Uveal Melanoma is a phase 3 interventional study registered as NCT07015190, led by IDEAYA Biosciences, and recruiting on the registry. Official title: A Randomised, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10). Planned enrolment is 520 participants (estimated). The study started in 2026-01-25 and primary completion is expected in 2030-10. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: OptimUM-10
- Tags: ctgov-ingest
- Registry id: NCT07015190
- Phase: 3
- Setting: A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)
- Sponsor: IDEAYA Biosciences
- Enrolled: 520

## Sources

- ClinicalTrials.gov NCT07015190: https://clinicaltrials.gov/study/NCT07015190

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Darovasertib](https://onco.cc/drugs/darovasertib/)
- companies: [IDEAYA Biosciences](https://onco.cc/companies/ideaya-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07015190.json